Pharmaceutical Support

The Prevent Cancer Foundation® is a national nonprofit organization whose mission is saving lives across all populations through cancer prevention and early detection.  The Foundation receives funding from a diverse group of companies, enabling the Foundation to support research, education, outreach (including screening programs) and advocacy across the U.S. to prevent cancer or detect it early.  Included among these funders are pharmaceutical, biotechnology and medical device companies.

Support from the pharmaceutical industry includes:

  • Bringing attention to specific issues and needs in the prevention and early detection of cancer.
  • Assist in educating the public on how they can reduce their cancer risk, or detect cancer early, when successful treatment is more likely.
  • Provide scientific expertise for educational materials, exhibits, and the Foundation’s conferences and workshops.

While the Prevent Cancer Foundation® values its partnership with the pharmaceutical industry, it does not endorse any medical product, treatment protocol or service, nor does it provide medical advice to patients.

In addition, the Prevent Cancer Foundation® does not link its website to any product-specific websites, and has exclusive authority over content, procedures and processes.

2017 pharmaceutical contributions:  $1,451,000.00

  • Abbott Laboratories
  • AbbVie, Inc.
  • AmerisourceBergen
  • Amgen
  • Astellas Pharma
  • Bayer Healthcare
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Oncology
  • Celgene Corporation
  • Eisai Inc.
  • EMD Serono, Inc.
  • Epigenomics, Inc.
  • Exact Sciences Corporation
  • Genentech, Inc.
  • Gilead Sciences
  • Helsinn Group
  • Hologic, Inc.
  • Johnson & Johnson
  • Lilly USA, LLC
  • Merck & Co., Inc.
  • Mylan Laboratories, Inc.
  • Myriad Genetics, Inc.
  • Novartis Pharmaceuticals Corporation
  • Otsuka America Pharmaceutical, Inc.
  • Pfizer Inc.
  • Quest Diagnostics
  • Taiho Oncology
  • Takeda Pharmaceuticals International Co.
  • Tesaro
  • Teva Pharmaceuticals

Percentage of total Foundation revenue:  21%